Skip to main content
. 2022 Mar 25;23(7):3567. doi: 10.3390/ijms23073567

Figure 3.

Figure 3

Zafirlukast does not trigger caspase-dependent apoptosis or necroptosis. (A) 786-O and 293T cells were pre-treated with the pan-caspase inhibitor zVAD.fmk (20 μM), the RIPK3 inhibitor GSK’872 (20 μM), the RIPK1 inhibitor Nec-1s (25 μM) or the MLKL inhibitor NSA (1 μM), followed by treatments with DMSO or 100 μM zafirlukast for 24 h, after which cell death was determined by quantifying PI uptake. Data are presented as percentage of PI-positive cells and mean and SD of three independent experiments performed in triplicate are shown. *** p < 0.001, n.s.: non-significant; (B) As in (A), but HT-29 and 786-O cells were treated with the indicated inhibitor/zafirlukast combinations. Data are presented as percentage of PI-positive cells and mean and SD of three independent experiments performed in triplicate are shown. *** p < 0.001.